Brinckerhoff Quoted on Mayo v. Prometheus

20 March 2012 Reuters News


Discussing the Supreme Court’s decision in Mayo v. Prometheus to reject two patents on a method for monitoring a patient’s blood to determine appropriate drug dosage as well as the decision's potential to affect the profitability of personalized medicine, Partner Courtenay Brinckerhoff said the rejection is a disruption of the status quo that may result in less funding for research. First published in an article that appeared in Reuters, Ms. Brinckerhoff’s comments later appeared in additional publications including the Chicago Tribune, Yahoo! News, BioPortfolio and The Huffington Post.

Related Services